[go: up one dir, main page]

BR9911291A - Diagnóstico diferencial de neurodegeneração - Google Patents

Diagnóstico diferencial de neurodegeneração

Info

Publication number
BR9911291A
BR9911291A BR9911291-4A BR9911291A BR9911291A BR 9911291 A BR9911291 A BR 9911291A BR 9911291 A BR9911291 A BR 9911291A BR 9911291 A BR9911291 A BR 9911291A
Authority
BR
Brazil
Prior art keywords
neurodegeneration
differential diagnosis
methods
quantification
relates
Prior art date
Application number
BR9911291-4A
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Andre Van Devoorde
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR9911291A publication Critical patent/BR9911291A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Eye Examination Apparatus (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"DIAGNóSTICO DIFERENCIAL DE NEURODEGENERAçãO". Apresente invenção se refere a novos processos para a detecçãoespecífica, quantificação e/ou diagnóstico diferencial deneurodegeneração em um indivíduo empregando um ensaio emcombinação que detecta pelo menos três marcadores neurológicosem um ou mais fluidos corporais do indivíduo, sendo o tipo e o graude degeneração um reflexo das alterações quantitativas no nívelde todos os marcadores em comparação com a amostra decontrole. A presente invenção também se refere a processos paraa detecção de Rab3a, SNAP25 e <244>-sinucleína no fluidocérebro-espinhal e ao emprego destes processos em um ensaio emcombinação para a detecção específica, quantificação e/oudiagnóstico diferencial de neurodegeneração.
BR9911291-4A 1998-07-03 1999-06-29 Diagnóstico diferencial de neurodegeneração BR9911291A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870148 1998-07-03
EP98870236 1998-11-03
EP99870069 1999-04-09
PCT/EP1999/004483 WO2000002053A2 (en) 1998-07-03 1999-06-29 Differential diagnosis of neurodegeneration

Publications (1)

Publication Number Publication Date
BR9911291A true BR9911291A (pt) 2001-12-04

Family

ID=27239769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911291-4A BR9911291A (pt) 1998-07-03 1999-06-29 Diagnóstico diferencial de neurodegeneração

Country Status (11)

Country Link
EP (1) EP1095278B1 (pt)
JP (3) JP2002519702A (pt)
CN (1) CN1316055A (pt)
AT (1) ATE312349T1 (pt)
AU (1) AU754062B2 (pt)
BR (1) BR9911291A (pt)
CA (1) CA2329523A1 (pt)
DE (1) DE69928809T2 (pt)
DK (1) DK1095278T3 (pt)
ES (1) ES2255280T3 (pt)
WO (1) WO2000002053A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2002256677A1 (en) * 2001-03-15 2002-10-03 Novartis Ag Screening for drugs against disorders associated with schizophrenia
KR100506766B1 (ko) * 2001-11-20 2005-08-05 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및이를 포함하는 융합단백질
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
AT500321B1 (de) * 2003-12-30 2006-02-15 Red Bull Gmbh Verfahren zur diagnose des down-syndroms
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CA2589700A1 (en) * 2004-12-01 2006-07-13 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
EP2437067B1 (en) * 2006-11-17 2015-03-18 Friedrich-Alexander-Universität Erlangen-Nürnberg Method of Differentially Diagnosing Dementias
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
JP2009052933A (ja) * 2007-08-24 2009-03-12 Rakuno Gakuen プリオン病の検出方法及び診断キット
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009086306A1 (en) 2007-12-21 2009-07-09 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease
JP5778678B2 (ja) * 2009-09-16 2015-09-16 ユナイティッド アラブ エミレーツ ユニヴァーシティ パーキンソン病の診断薬
WO2012141674A2 (en) 2010-01-26 2012-10-18 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
CN106397588B (zh) 2010-02-26 2020-09-08 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
WO2011123844A2 (en) * 2010-04-01 2011-10-06 Banyan Biomarkers, Inc. Markers and assays for detection of neurotoxicity
GB201011420D0 (en) * 2010-07-06 2010-08-18 United Arab Emirates Universit Method for diagnosis
RU2441240C1 (ru) * 2010-10-05 2012-01-27 Государственное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет" Министерства здравоохранения и социального развития Российской Федерации Способ диагностики аксонально-демиелинизирующих полиневропатий
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10942190B2 (en) 2014-01-21 2021-03-09 Shimadzu Corporation Measurement method for amyloid precursor protein cleavage peptides
CN106574930B (zh) 2014-05-22 2019-09-03 株式会社岛津制作所 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
CN113267630A (zh) * 2014-09-10 2021-08-17 艾伯维德国有限责任两合公司 基于RGMa片段的诊断测定
JP6467512B2 (ja) * 2015-09-16 2019-02-13 株式会社島津製作所 脳内のアミロイドβ蓄積状態を評価するマルチプレックスバイオマーカー及びその分析方法
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
CA3044048A1 (en) * 2016-11-16 2018-05-24 Nanosomix, Inc. Quantification of subpopulations of exosomes and diagnosis of neurodegenerative disorders
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
GB201814807D0 (en) * 2018-09-12 2018-10-24 Univ Newcastle Dementia Biomarkers
LT3660509T (lt) * 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
GB202005732D0 (en) * 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
EP4172199B1 (en) 2020-06-26 2025-05-14 BioArctic AB Alpha-synuclein protofibril-binding antibodies
JP2023551542A (ja) * 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価

Also Published As

Publication number Publication date
CA2329523A1 (en) 2000-01-13
JP2010019864A (ja) 2010-01-28
AU754062B2 (en) 2002-10-31
WO2000002053A3 (en) 2000-02-24
EP1095278B1 (en) 2005-12-07
DK1095278T3 (da) 2006-04-18
JP2002519702A (ja) 2002-07-02
ATE312349T1 (de) 2005-12-15
HK1036834A1 (en) 2002-01-18
ES2255280T3 (es) 2006-06-16
JP2006091025A (ja) 2006-04-06
WO2000002053A2 (en) 2000-01-13
JP4580455B2 (ja) 2010-11-10
AU5029099A (en) 2000-01-24
CN1316055A (zh) 2001-10-03
DE69928809T2 (de) 2006-08-31
DE69928809D1 (de) 2006-01-12
EP1095278A2 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
BR9911291A (pt) Diagnóstico diferencial de neurodegeneração
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
DE60228684D1 (de) System zur überwachung der konzentration von analyten in körperflüssigkeiten
DK1381866T3 (da) Fremgangsmåde til differentialdiagnosticering af Alzheimers demens samt anordning hertil
DE60233949D1 (de) Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
ATE417125T1 (de) Diagnose von einer klinischen infektion einer wunde
WO2004063753A3 (en) A serum marker for measuring liver fibrosis
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
AU5146896A (en) Assaying protein fragments in body fluids
WO2002016943A3 (en) Differential immunoassay
DE50104561D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
FR2664702B1 (fr) Procede de reduction d&#39;interferences dans un dosage par fluorescence.
KR960705211A (ko) 체액내 bpi의 정량 방법(method for quantifying bpi in body fluids)
ATE377192T1 (de) Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
DK0958500T3 (da) Immunohistokemisk påvisningsassay for carcinomproliferationsstatus
DK0720745T3 (da) Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
DK1664330T3 (da) Blod- og urintest
PT1297342E (pt) Metodo de diagnostico para a doenca de alzheimer com base em holo-transcobalamina ii
PT1218749E (pt) Sistema de deteccao de cancro da prostata atraves da analise do psa/igf-l livre
WO2001096599A3 (en) Methods for quantitative determination of b-fibronectin in biological fluids and tissues
FI100557B (fi) Vapaan trypsinogeeni-2:n määritys

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5,6,7 E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.